RELATED STUDY
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.
Key Findings: Although, many open questions await to be answered, pharmacological modulation of the (endo)cannabinoid signaling, and restoration of the homeostatic eCB tone of the tissues augur to be very promising future directions in the management of several pathological inflammation-accompanied diseases.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Hungary
Year of Pub: 2017
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Cannabinoid (unspecified), Synthetic Cannabinoid (unspecified), Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, GPCR 18, GPCR 55, Opioid Receptor Delta, TRPA1, TRPV1, TRPV2, TRPV4, TRPM8, GPCR, TRPs, PPARs
Ligands Studied: Anti-inflammatory cytokines, Dopamine, Epinephrine, Serotonin, Neurotransmitter (unspecified/other)
